Vasomotor Symptoms Clinical Trial
Official title:
The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS SR in Women With Vasomotor Symptoms Associated With Menopause: The PRIMMUS (PRIstiq for Managing Menopause and Understanding Symptoms) Study
Verified date | October 2011 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
Desvenlafaxine succinate (DVS SR) is a serotonin and norepinephrine reuptake inhibitor (SNRI). It is a nonhormonal option for the treatment of Vasomotor Symptoms (VMS) associated with menopause. Nausea is the most common adverse event that is observed in clinical studies and is the main reason for discontinuation during the first week of therapy. Other adverse events (headache, nausea, and dizziness) associated with DVS SR have been noted to occur when subjects abruptly discontinue the medication. The purpose of this study is to evaluate several titration and tapering regimens of DVS SR to ensure a better tolerability profile at the start and completion of treatment. In addition, this study will provide a long posttreatment follow-up to assess any symptoms after treatment is discontinued.
Status | Completed |
Enrollment | 500 |
Est. completion date | January 2008 |
Est. primary completion date | January 2008 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Generally healthy, postmenopausal woman who seeks treatment for hot flushes. - Meets 1 of the following: At least 12 months of spontaneous amenorrhea; At least 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL; At least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy). Hysterectomized without bilateral oophorectomy and with serum FSH levels >40 mIU/mL. Exclusion Criteria: - History of a seizure disorder other than a single childhood febrile seizure. - History or presence of clinically important hepatic or renal disease or other medical disease. - Presence or recent history of major depressive disorder, bipolar disorder, psychotic disorder, or generalized anxiety disorder requiring therapy. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Pfizer Investigational Site | Calgary | Alberta |
Canada | Pfizer Investigational Site | Coquitlam | British Columbia |
Canada | Pfizer Investigational Site | Langley | British Columbia |
Canada | Pfizer Investigational Site | Montreal | Quebec |
Canada | Pfizer Investigational Site | Newmarket | Ontario |
Canada | Pfizer Investigational Site | Pointe Claire | Quebec |
Canada | Pfizer Investigational Site | Quebec | |
Canada | Pfizer Investigational Site | Sarnia | Ontario |
Canada | Pfizer Investigational Site | Shawinigan | Quebec |
Canada | Pfizer Investigational Site | Sherbrooke | Quebec |
Canada | Pfizer Investigational Site | St-Romuald | Quebec |
Canada | Pfizer Investigational Site | St. John's | Newfoundland and Labrador |
Canada | Pfizer Investigational Site | Surrey | British Columbia |
Canada | Pfizer Investigational Site | Toronto | Ontario |
Canada | Pfizer Investigational Site | Toronto | Ontario |
Canada | Pfizer Investigational Site | Toronto | Ontario |
Canada | Pfizer Investigational Site | Unknown | Quebec |
Canada | Pfizer Investigational Site | Winnipeg | Manitoba |
Canada | Pfizer Investigational Site | Winnipeg | Manitoba |
United States | Pfizer Investigational Site | Albuquerque | New Mexico |
United States | Pfizer Investigational Site | Albuquerque | New Mexico |
United States | Pfizer Investigational Site | Beverly Hills | California |
United States | Pfizer Investigational Site | Billings | Montana |
United States | Pfizer Investigational Site | Bismarck | North Dakota |
United States | Pfizer Investigational Site | Canton | Michigan |
United States | Pfizer Investigational Site | Carrollton | Texas |
United States | Pfizer Investigational Site | Champaign | Illinois |
United States | Pfizer Investigational Site | Chapel Hill | North Carolina |
United States | Pfizer Investigational Site | Charlotte | North Carolina |
United States | Pfizer Investigational Site | Chicago | Illinois |
United States | Pfizer Investigational Site | Clearwater | Florida |
United States | Pfizer Investigational Site | Cleveland | Ohio |
United States | Pfizer Investigational Site | Crystal River | Florida |
United States | Pfizer Investigational Site | Deland | Florida |
United States | Pfizer Investigational Site | Denver | Colorado |
United States | Pfizer Investigational Site | Encinitas | California |
United States | Pfizer Investigational Site | Eugene | Oregon |
United States | Pfizer Investigational Site | Fargo | North Dakota |
United States | Pfizer Investigational Site | Foothill Ranch | California |
United States | Pfizer Investigational Site | Gainesville | Florida |
United States | Pfizer Investigational Site | Houston | Texas |
United States | Pfizer Investigational Site | Hurst | Texas |
United States | Pfizer Investigational Site | Idaho Falls | Idaho |
United States | Pfizer Investigational Site | Lake Worth | Florida |
United States | Pfizer Investigational Site | Las Vegas | Nevada |
United States | Pfizer Investigational Site | Lebanon | New Hampshire |
United States | Pfizer Investigational Site | Lexington | Kentucky |
United States | Pfizer Investigational Site | Longmont | Colorado |
United States | Pfizer Investigational Site | Louisville | Kentucky |
United States | Pfizer Investigational Site | Metairie | Louisiana |
United States | Pfizer Investigational Site | Metairie | Louisiana |
United States | Pfizer Investigational Site | Miami | Florida |
United States | Pfizer Investigational Site | Miami | Florida |
United States | Pfizer Investigational Site | Miami | Florida |
United States | Pfizer Investigational Site | Midland | Texas |
United States | Pfizer Investigational Site | New Brunswick | New Jersey |
United States | Pfizer Investigational Site | New York | New York |
United States | Pfizer Investigational Site | Norfolk | Virginia |
United States | Pfizer Investigational Site | Norfolk | Virginia |
United States | Pfizer Investigational Site | Omaha | Nebraska |
United States | Pfizer Investigational Site | Palm Harbor | Florida |
United States | Pfizer Investigational Site | Pittsburgh | Pennsylvania |
United States | Pfizer Investigational Site | San Diego | California |
United States | Pfizer Investigational Site | San Diego | California |
United States | Pfizer Investigational Site | Seattle | Washington |
United States | Pfizer Investigational Site | South Bend | Indiana |
United States | Pfizer Investigational Site | Tampa | Florida |
United States | Pfizer Investigational Site | Tucson | Arizona |
United States | Pfizer Investigational Site | Tucson | Arizona |
United States | Pfizer Investigational Site | Upland | California |
United States | Pfizer Investigational Site | Watertown | South Dakota |
United States | Pfizer Investigational Site | Winston-Salem | North Carolina |
United States | Pfizer Investigational Site | Winston-Salem | North Carolina |
United States | Pfizer Investigational Site | Ypsilanti | Michigan |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Nausea During the First 2 Weeks of Treatment | Nausea by spontaneous reports to the investigators was counted if it was reported during first 2 weeks of treatment, and it was not seen before the first dose of treatment, or if it was seen before the first dose and the symptoms got worse. If multiple incidences occurred on the same participant during the 2 weeks, only 1 incidence was counted. | Baseline up to Week 2 | Yes |
Primary | Discontinuation Emergent Signs and Symptoms (DESS) Total Score at the End of First Week of Tapering | DESS: a clinician-administered 43-item assessment that evaluates discontinuation-emergent symptoms resulting from the withdrawal from test article. The DESS total score is the sum of the number of "new symptoms" and "old (but worse) symptoms" (1) and 0 for "old and unchanged symptom", "absent", or "old symptom but improved" for a total possible range of 0 to 43. A higher score indicates more symptoms. | Week 17 | Yes |
Primary | DESS Total Score at End of Second Week of Tapering | DESS: a clinician-administered 43-item assessment that evaluates discontinuation-emergent symptoms resulting from the withdrawal from test article. The DESS total score is the sum of the number of "new symptoms" and "old (but worse) symptoms" (1) and 0 for "old and unchanged symptom", "absent", or "old symptom but improved" for a total possible range of 0 to 43. A higher score indicates more symptoms. | Week 18 | Yes |
Primary | DESS Total Score at 1 Week After the End of Tapering | DESS: a clinician-administered 43-item assessment that evaluates discontinuation-emergent symptoms resulting from the withdrawal from test article. The DESS total score is the sum of the number of "new symptoms" and "old (but worse) symptoms" (1) and 0 for "old and unchanged symptom", "absent", or "old symptom but improved" for a total possible range of 0 to 43. A higher score indicates more symptoms. | Week 19 | Yes |
Secondary | Number of Participants With Other Spontaneously Reported Adverse Events (AEs) in First 2 Weeks of Treatment | Any untoward medical occurrence in a participant who received study drug was considered an AE, without regard to possibility of causal relationship. | Baseline up to Week 2 | Yes |
Secondary | Percentage of Participants Discontinuing Treatment Due to AEs in First 2 Weeks of Treatment | Any untoward medical occurrence in a participant who received study drug was considered an AE, without regard to possibility of causal relationship. | Baseline up to Week 2 | Yes |
Secondary | Number of Participants With Each DESS at the End of First Week of Tapering | DESS: a clinician-administered 43-item assessment that evaluates discontinuation-emergent symptoms resulting from the withdrawal from test article. | Week 17 | Yes |
Secondary | Number of Participants With Each DESS at the End of Second Week of Tapering | DESS: a clinician-administered 43-item assessment that evaluates discontinuation-emergent symptoms resulting from the withdrawal from test article. | Week 18 | Yes |
Secondary | Number of Participants With Each DESS One Week After End of Tapering | DESS: a clinician-administered 43-item assessment that evaluates discontinuation-emergent symptoms resulting from the withdrawal from test article. | Week 19 | Yes |
Secondary | Number of Participants Showing Satisfaction With Tolerability During the First Two Weeks of Treatment | Satisfaction with tolerability (lack of bothersomeness) was assessed using a questionnaire via an interactive voice response system (IVRS)/interactive web based response system (IWRS), and evaluated based on participants' response of extremely satisfied, satisfied, neutral, dissatisfied or extremely dissatisfied with the study medication. | Week 1 and Week 2 | No |
Secondary | Number of Participants Showing Satisfaction With Tolerability at the End of Tapering | Satisfaction with tolerability (lack of bothersomeness) was assessed using a questionnaire via an IVRS/IWRS and evaluated based on participants' response of extremely satisfied, satisfied, neutral, dissatisfied or extremely dissatisfied with the study medication. | Week 19 | No |
Secondary | Menopause Symptoms-treatment Satisfaction Questionnaire (MS-TSQ) Score | MS-TSQ is a questionnaire assessing participants' degree of satisfaction with regard to the test article which was administered to the participants via an IVRS/IWRS. The questionnaire comprised 8 questions and each was rated on a scale from 0 (extremely dissatisfied) to 4 (extremely satisfied). | Week 16 | No |
Secondary | Change From Baseline in Menopause-specific Quality of Life Questionnaire (MenQOL) Score at Week 4, Week 8, Week 12 and Week 16 | MenQOL questionnaire assessed how bothered participants were with 31 symptoms. It contains domains: vasomotor (items 1-3); psychosocial (items 4-10); physical (items 11-26); sexual (items 27-29); in addition to nausea and indigestion. 31 individual symptoms are rated on a scale of 0 (not at all bothered) to 6 (extremely bothered). Total possible score ranged from 0 to 186. MenQOL summary score was calculated as mean of four domain scores (Physical function, Psychosocial function, Sexual function and Vasomotor function) ranging from 1 to 8, with higher scores indicating worse quality of life. | Baseline, Week 4, Week 8, Week 12 and Week 16 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04090957 -
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT01052454 -
Mindfulness-Based Stress Reduction for Hot Flashes
|
Phase 0 | |
Completed |
NCT00535288 -
Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)
|
Phase 3 | |
Recruiting |
NCT00906308 -
A Study of MF101 in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT01452373 -
Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT00560833 -
Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)
|
Phase 3 | |
Completed |
NCT05033886 -
A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause
|
Phase 3 | |
Completed |
NCT05083884 -
A Survey About Hot Flashes in Women Going Through the Menopause
|
||
Completed |
NCT01178892 -
MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation
|
N/A | |
Completed |
NCT00397176 -
Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women
|
Phase 1 | |
Recruiting |
NCT06122181 -
Study of HS-10384 in Participants of Chinese Postmenopausal Women
|
Phase 1 | |
Not yet recruiting |
NCT06393673 -
A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women
|
Phase 2 | |
Withdrawn |
NCT02202707 -
Vasomotor Symptoms and Cardiovascular Control
|
N/A | |
Completed |
NCT00356447 -
Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.
|
Phase 3 | |
Completed |
NCT05312567 -
FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms
|
Phase 2 | |
Terminated |
NCT01353963 -
Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
|
Phase 4 | |
Completed |
NCT00446199 -
Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
|
Phase 3 | |
Completed |
NCT05850338 -
Determination of the Effects of Autogenic Relaxation Exercise and Cold Pillow Application on Vasomotor Symptom Control and Quality of Life in Postmenopausal Women
|
N/A | |
Completed |
NCT02803268 -
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms
|
Phase 1 | |
Completed |
NCT00683800 -
Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women
|
Phase 3 |